Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828955 | 1.00 | ADRA1A (0.64) | ADRA1AEPHX1PRMT1PLA2G2AEPHX2 | |
| SCHEMBL7123668 | 1.00 | ADRA1A (0.64) | ADRA1AEPHX1PRMT1PLA2G2AEPHX2 | |
| SCHEMBL4704932 | 0.98 | ADRA1A (0.61) | ADRA1AEPHX1PRMT1PLA2G2AEPHX2 | |
| SCHEMBL13213196 | 0.94 | ADRA1A (0.58) | ADRA1AEPHX1PRMT1PLA2G2AEPHX2 | |
| SCHEMBL628018 | 0.91 | EPHX1 (0.57) | ADRA1AEPHX1PRMT1PLA2G2AEPHX2 | |
| SCHEMBL7788569 | 0.87 | EPHX1 (0.82) | EPHX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL14252129 | 0.87 | EPHX1 (0.82) | EPHX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL7788927 | 0.87 | EPHX1 (0.82) | EPHX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL717081 | 0.87 | EPHX1 (0.82) | EPHX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL7788937 | 0.87 | EPHX1 (0.82) | EPHX1ALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994535-B1 | PRODUCTION OF MYXOPYRONIN AND OF ITS DERIVATIVES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2018-12-05 | — | — | EP | disclosed |
| EP-2994535-A1 | PRODUCTION OF MYXOPYRONIN AND OF ITS DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014181000-A1 | PRODUCTION OF MYXOPYRONIN AND OF ITS DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2014-11-13 | — | — | WO | disclosed |
| US-6916947-B2 | Method of producing amino carboxylic acids | DEGUSSA AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20030120084-A1 | Method of producing amino carboxylic acids | DEGUSSA AG | 2003-06-26 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120084-A1 | Method of producing amino carboxylic acids | CA1, CA3, CA13 | ADRA1A 3417/4885EPHX1 4332/4885PRMT1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.